enGene Holdings Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENGN Nasdaq 2836 www.engene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for enGene Holdings Inc.

enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment - Feb 12th, 2026 3:02 am
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 4th, 2026 6:00 am
Both private equity firms who control a good portion of enGene Holdings Inc. (NASDAQ:ENGN) along with institutions must be dismayed after last week's 16% decrease - Feb 2nd, 2026 3:50 am
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls - Jan 30th, 2026 7:54 am
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. - Jan 20th, 2026 3:35 pm
enGene Reports Full Year 2025 Financial Results and Provides Business Update - Dec 22nd, 2025 2:03 pm
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors - Dec 16th, 2025 8:00 am
enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial - Dec 4th, 2025 8:09 pm
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness - Dec 2nd, 2025 5:30 am
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference - Nov 25th, 2025 5:30 am
enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results - Nov 13th, 2025 1:17 am
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants - Nov 12th, 2025 10:27 pm
enGene Announces Proposed Public Offering of Common Shares - Nov 12th, 2025 2:01 pm
enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial - Nov 11th, 2025 10:04 am
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday - Nov 11th, 2025 7:15 am
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Tuesday as Investors Assess Impact of Government Shutdown - Nov 11th, 2025 6:40 am
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months - Nov 11th, 2025 5:30 am
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial - Nov 10th, 2025 2:05 pm
enGene to Participate in Upcoming Investor Conferences - Nov 6th, 2025 3:00 pm
enGene Named a BioSpace 2026 Best Places to Work Winner - Nov 4th, 2025 11:35 am